Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Set out priority areas for quality improvement in health and social care.
Guidance by programme
Advice by programme
Products being developed or updated
Guidance, quality standards and advice being developed.
News on this topic
NICE has updated its managing COVID-19 guideline to include new recommendations on using monoclonal antibodies to treat COVID-19 patients in hospital.
NICE has updated its advice on two therapeutics for managing COVID-19 – remdesivir and colchicine.
Putting guidance into practice
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 15 shared learning examples for this topic: